Home Tools
Log in
Cart

c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T9052 XL092 2367004-54-2 99.51%
XL092
XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
T5S1331 Herbacetin 527-95-7 99.51%
Herbacetin
1. Herbacetin induces apoptosis in HepG2 cells, by ROS and PI3K/Akt pathway. 2. Herbacetin suppresses the HGF-induced motility of human breast cancer MDA-MB-231 ...
T2185 L-Ascorbic acid 2-phosphate trisodium 66170-10-3 99.5%
L-Ascorbic acid 2-phosphate trisodium
L-Ascorbic acid 2-phosphate trisodium (Sodium ascorbyl phosphate) is used in biocatalytic dephosphorylation for electric power generation and electrochemical det...
T10585 Bozitinib 1440964-89-5 99.48%
Bozitinib
Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional AT...
T4426 CEP-40783 1437321-24-8 99.45%
CEP-40783
CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
T5478 SRI 31215 TFA 1832686-44-8 99.36%
SRI 31215 TFA
SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF ...
T6128 PHA-665752 477575-56-7 99.35%
PHA-665752
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
T1661 Crizotinib 877399-52-5 99.35%
Crizotinib
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
T22324 Ensartinib hydrochloride 2137030-98-7 99.29%
Ensartinib hydrochloride
Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known cr...
T6260 AMG-208 1002304-34-8 99.27%
AMG-208
AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
T8416 Capmatinib xHCl 1029714-89-3 99.24%
Capmatinib xHCl
Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 =...
T2699 BMS 777607 1025720-94-8 99.22%
BMS 777607
BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of ...
T6351 MGCD-265 analog 875337-44-3 99.21%
MGCD-265 analog
MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 n...
T13108 Pamufetinib 1190836-34-0 99.15%
Pamufetinib
Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rME...
T1797 Cabozantinib S-malate 1140909-48-3 98.87%
Cabozantinib S-malate
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with pot...
T2349 BMS-754807 1001350-96-4 98.86%
BMS-754807
Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine ...
T8409 SYN1143 913376-84-8 98.86%
SYN1143
SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50...
T15617 JNJ-38877618 943540-74-7 98.84%
JNJ-38877618
JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).
T3550 X-376 1365267-27-1 98.72%
X-376
X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic...
T2680 NVP-BVU972 1185763-69-2 98.61%
NVP-BVU972
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
XL092
T9052
XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Herbacetin
T5S1331
1. Herbacetin induces apoptosis in HepG2 cells, by ROS and PI3K/Akt pathway. 2. Herbacetin suppresses the HGF-induced motility of human breast cancer MDA-MB-231 ...
L-Ascorbic acid 2-phosphate trisodium
T2185
L-Ascorbic acid 2-phosphate trisodium (Sodium ascorbyl phosphate) is used in biocatalytic dephosphorylation for electric power generation and electrochemical det...
Bozitinib
T10585
Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional AT...
CEP-40783
T4426
CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
SRI 31215 TFA
T5478
SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF ...
PHA-665752
T6128
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
Crizotinib
T1661
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
Ensartinib hydrochloride
T22324
Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known cr...
AMG-208
T6260
AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
Capmatinib xHCl
T8416
Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 =...
BMS 777607
T2699
BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of ...
MGCD-265 analog
T6351
MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 n...
Pamufetinib
T13108
Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rME...
Cabozantinib S-malate
T1797
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with pot...
BMS-754807
T2349
Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine ...
SYN1143
T8409
SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50...
JNJ-38877618
T15617
JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).
X-376
T3550
X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic...
NVP-BVU972
T2680
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
1 2 3 4 5
TargetMol